

CONTENTS

NOTE TO THE READER	11
LIST OF PARTICIPANTS	13
PREAMBLE	
Background	19
Objective and Scope	19
Selection of Topics for Monographs	20
Data for Monographs	21
The Working Group	21
Working Procedures	21
Exposure Data	22
Biological Data Relevant to the Evaluation of Carcinogenicity to Humans	24
Evidence for Carcinogenicity in Experimental Animals	25
Other Relevant Data in Experimental Systems and in Humans	27
Evidence for Carcinogenicity in Humans	29
Summary of Data Reported	32
Evaluation	33
References	37
GENERAL REMARKS	41
THE MONOGRAPHS	
Chromium and chromium compounds	
1. Chemical and physical data	49
1.1 Synonyms, trade names and molecular formulae of chromium and selected chromium-containing substances	49
1.2 Chemical and physical properties of pure substances	55
1.3 Technical products and impurities	55
(a) Chromite ore	55

CONTENTS

(b) Metallic chromium and chromium alloys	60
(c) Chromium[III] compounds	64
(d) Chromium[VI] compounds	65
2. Production, use, occurrence and analysis	66
2.1 Production	66
(a) Chromite ore	66
(b) Metallic chromium and chromium alloys	66
(c) Chromium[III] compounds	70
(d) Chromium[VI] compounds	72
(e) Other chromium compounds	78
2.2 Use	78
(a) Chromite ore	78
(b) Metallic chromium and chromium alloys	79
(c) Chromium[III] compounds	80
(d) Chromium[VI] compounds	81
(e) Other chromium compounds	84
2.3 Occurrence	84
(a) Natural occurrence	84
(b) Occupational exposures	85
(c) Air	98
(d) Water	99
(e) Soil and plants	101
(f) Food	101
(g) Animal tissues	101
(h) Human tissues and secretions	104
(i) Regulatory status and guidelines	104
2.4 Analysis	107
3. Biological data relevant to the evaluation of carcinogenic risk to humans	115
3.1 Carcinogenicity studies in animals	115
(a) Metallic chromium	115
(b) Chromium[III] compounds	118
(c) Chromium[VI] compounds	121
(d) Other chromium compounds	130
3.2 Other relevant data in experimental systems	143
(a) Absorption, distribution, excretion and metabolism	143

CONTENTS

(b) Toxic effects	147
(c) Effects on reproduction and prenatal toxicity	150
(d) Genetic and related effects	151
3.3 Other relevant data in humans	181
(a) Absorption, distribution, excretion and metabolism	181
(b) Toxic effects	182
(c) Effects on reproduction and prenatal toxicity	184
(d) Genetic and related effects	184
3.4 Case reports and epidemiological studies of carcinogenicity to humans	187
(a) Chromate production	187
(b) Production of chromate pigments	198
(c) Chromium plating	201
(d) Production of ferrochromium alloys	204
(e) Other industrial exposures to chromium	205
(f) Environmental exposure to chromium	207
4. Summary of data reported and evaluation	208
4.1 Exposure data	208
4.2 Experimental carcinogenicity data	208
4.3 Human carcinogenicity data	210
4.4 Other relevant data	211
4.5 Evaluation	213
5. References	214

Nickel and nickel compounds

1. Chemical and physical data	257
1.1 Synonyms, trade names and molecular formulae of nickel and selected nickel-containing compounds	257
1.2 Chemical and physical properties of pure substances	262
1.3 Technical products and impurities	267
(a) Metallic nickel and nickel alloys	267
(b) Nickel oxides and hydroxides	267
(c) Nickel sulfides	269
(d) Nickel salts	270
(e) Other nickel compounds	270

CONTENTS

2.	Production, use, occurrence and analysis	270
2.1	Production	270
(a)	Metallic nickel and nickel alloys	270
(b)	Nickel oxides and hydroxides	277
(c)	Nickel sulfides	278
(d)	Nickel salts	278
(e)	Other nickel compounds	279
2.2	Use	280
(a)	Metallic nickel and nickel alloys	281
(b)	Nickel oxides and hydroxides	282
(c)	Nickel sulfides	282
(d)	Nickel salts	282
(e)	Other nickel compounds	283
2.3	Occurrence	283
(a)	Natural occurrence	283
(b)	Occupational exposures	284
(c)	Air	302
(d)	Tobacco smoke	304
(e)	Water and beverages	304
(f)	Soil	305
(g)	Food	306
(h)	Human tissues and secretions	308
(i)	Iatrogenic exposures	308
(j)	Regulatory status and guidelines	311
2.4	Analysis	314
3.	Biological data relevant to the evaluation of carcinogenic risk to humans	318
3.1	Carcinogenicity studies in animals	318
(a)	Metallic nickel and nickel alloys	318
(b)	Nickel oxides and hydroxides	324
(c)	Nickel sulfides	328
(d)	Nickel salts	336
(e)	Other nickel compounds	340
3.2	Other relevant data in experimental systems	356
(a)	Absorption, distribution, excretion and metabolism	356
(b)	Dissolution and cellular uptake	360

CONTENTS

(c) Interactions	363
(d) Toxic effects	364
(e) Effects on reproduction and prenatal toxicity	370
(f) Genetic and related effects	374
3.3 Other relevant data in humans	383
(a) Absorption, distribution, excretion and metabolism	383
(b) Toxic effects	386
(c) Effects on reproduction and prenatal toxicity	388
(d) Genetic and related effects	388
3.4 Epidemiological studies of carcinogenicity to humans	389
(a) Introduction	389
(b) Nickel mining, smelting and refining	391
(c) Nickel alloy and stainless-steel production	397
(d) Other industrial exposures to nickel	398
(e) Other studies	400
4. Summary of data reported and evaluation	401
4.1 Exposure data	401
4.2 Experimental carcinogenicity data	405
4.3 Human carcinogenicity data	407
4.4 Other relevant data	408
4.5 Evaluation	410
5. References	411

Welding

1. Historical perspectives and process description	447
1.1 Introduction	447
1.2 Development of welding in the twentieth century	447
1.3 Description of major welding processes	450
(a) Introduction	450
(b) Manual metal arc welding	452
(c) Metal inert gas welding	452
(d) Flux-cored wire welding	453
(e) Tungsten inert gas welding	453
(f) Submerged arc welding	454
1.4 Number and distribution of welders	454

CONTENTS

2.	Welding fumes and gases	455
2.1	Introduction	455
2.2	Chemical composition and physical properties of welding fumes .	457
(a)	Elemental composition	457
(b)	Oxidation state of chromium	459
(c)	Crystalline materials	460
(d)	Physical properties	462
2.3	Occupational exposures of welders	463
(a)	Exposures to welding fumes	463
(b)	Biological monitoring of exposure	465
(c)	Exposures to welding gases	471
(d)	Exposures to organic constituents of welding fumes	472
(e)	Other exposures	472
(f)	Regulatory status and guidelines	474
2.4	Chemical analysis of welding fumes and gases	474
3.	Biological data relevant to the evaluation of carcinogenic risk to humans	476
3.1	Carcinogenicity studies in animals	476
(a)	Intratracheal instillation	476
(b)	Intrabronchial implantation	476
3.2	Other relevant data in experimental systems	477
(a)	Absorption, distribution, excretion and metabolism	477
(b)	Toxic effects	479
(c)	Effects on reproduction and prenatal toxicity	482
(d)	Genetic and related effects	482
3.3	Other relevant data in humans	484
(a)	Absorption, distribution, excretion and metabolism	484
(b)	Toxic effects	485
(c)	Effects on reproduction and prenatal toxicity	487
(d)	Genetic and related effects	487
3.4	Case reports and epidemiological studies of carcinogenicity to humans	489
(a)	Case reports and descriptive epidemiology	489
(b)	Cohort studies	491
(c)	Case-control studies	498

CONTENTS

4.	Summary of data reported and evaluation	505
4.1	Exposure data	505
4.2	Experimental carcinogenicity data	505
4.3	Human carcinogenicity data	505
4.4	Other relevant data	506
4.5	Evaluation	507
5.	References	508
SUMMARY OF FINAL EVALUATIONS		527
APPENDIX 1. SUMMARY TABLES OF GENETIC AND RELATED EFFECTS		529
APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS		537
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES		649

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.